Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism.

[1]  Qibin Zhang,et al.  Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics , 2010, PLoS pathogens.

[2]  M. Yarmush,et al.  Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance , 2009, Proceedings of the National Academy of Sciences.

[3]  R. Hegele,et al.  Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptor–Null Mice With Diet-Induced Insulin Resistance , 2009, Diabetes.

[4]  F. Zoulim,et al.  Statins potentiate the in vitro anti‐hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development , 2009, Hepatology.

[5]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[6]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[7]  Raymond T Chung,et al.  Apolipoprotein B–dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin , 2008, Hepatology.

[8]  F. Chisari,et al.  Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion , 2007, Journal of Virology.

[9]  R. Bartenschlager,et al.  The lipid droplet is an important organelle for hepatitis C virus production , 2007, Nature Cell Biology.

[10]  J. Pekow,et al.  Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C‐related cirrhosis , 2007, Cancer.

[11]  M. Gale,et al.  Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins , 2007, Proceedings of the National Academy of Sciences.

[12]  R. Chung,et al.  Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial , 2007, Hepatology.

[13]  Richard E Gregg,et al.  Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[14]  Roger A. Davis,et al.  Coordinate Transcriptional Repression of Liver Fatty Acid-binding Protein and Microsomal Triglyceride Transfer Protein Blocks Hepatic Very Low Density Lipoprotein Secretion without Hepatosteatosis* , 2006, Journal of Biological Chemistry.

[15]  F. Chisari,et al.  Differential Biophysical Properties of Infectious Intracellular and Secreted Hepatitis C Virus Particles , 2006, Journal of Virology.

[16]  M. Kaito,et al.  Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin , 2006, Journal of viral hepatitis.

[17]  Yoko Takahashi,et al.  Activity and mRNA levels of enzymes involved in hepatic fatty acid oxidation in mice fed citrus flavonoids. , 2006, Nutrition.

[18]  F. Chisari,et al.  Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.

[19]  P. Desreumaux,et al.  Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. , 2005, World journal of gastroenterology.

[20]  Arnaud Pillon,et al.  Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands , 2005 .

[21]  D. Burton,et al.  Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Borradaile,et al.  Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. , 2005, Diabetes.

[23]  M. Gale,et al.  Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. , 2005, Molecular cell.

[24]  M. Ishikawa,et al.  Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. , 2005, Biological & pharmaceutical bulletin.

[25]  F. Chisari,et al.  Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Auwerx,et al.  Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. , 2005, Gastroenterology.

[27]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[28]  J. Lee,et al.  Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. , 2003, Clinical nutrition.

[29]  P. André,et al.  Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles , 2002, Journal of Virology.

[30]  G. Oh,et al.  Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. , 2001, Biochemical and biophysical research communications.

[31]  N. Borradaile,et al.  Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. , 2001, Journal of lipid research.

[32]  D. R. Taylor,et al.  Hepatitis C virus and interferon resistance. , 2000, Microbes and infection.

[33]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[34]  K. Agarwal,et al.  Treatment of hepatitis C infection , 1999, British medical journal.

[35]  N. Borradaile,et al.  Antiatherogenic Properties of Naringenin, a Citrus Flavonoid , 1999 .

[36]  J. Capone,et al.  Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Y. Ikehara,et al.  Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. , 1988, The Journal of biological chemistry.

[38]  R. Hegele,et al.  Naringenin prevents dyslipidemia, apoB overproduction and hyperinsulinemia in LDL-receptor null mice with diet-induced insulin resistance. Running title: Naringenin prevents dyslipidemia , 2009 .

[39]  M. Manns,et al.  The way forward in HCV treatment — finding the right path , 2008, Nature Reviews Drug Discovery.

[40]  S. Schreiber,et al.  A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. , 2007, Gastroenterology.

[41]  K. Jeong,et al.  Naringin time-dependently lowers hepatic cholesterol biosynthesis and plasma cholesterol in rats fed high-fat and high-cholesterol diet. , 2006, Journal of medicinal food.

[42]  J. Nicolas,et al.  Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. , 2005, Analytical biochemistry.

[43]  O. Chazouilleres,et al.  Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. , 2001, Journal of hepatology.

[44]  N. Borradaile,et al.  Hypocholesterolemic effects of dietary citrus juices in rabbits , 2000 .